Alcon acquires Tear Film Innovations

20 Dec 2018

Tear Film's iLux Device offers innovative, customizable treatment for Meibomian Gland Dysfunction, a leading cause of dry eye.

Alcon has acquired Tear Film Innovations, a privately-held company and manufacturer of the iLux Device, an innovative therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye.

Alcon acquires Tear Film Innovations

Handheld and portable, the iLux Device enables eye care professionals to directly target a patient's blocked meibomian glands and provide therapy through an in-office treatment. Using the iLux Device, a practitioner can warm the eyelids via disposable silicone pads to address blocked meibomian glands through the application of light-based heating. While applying the iLux Device, the practitioner can view the eyelid margin and apply manually-controlled compression to express blockages, making adjustments as needed to tailor treatment to the individual needs of the patient. Most treatments can be completed in a matter of minutes.

The Tear Film acquisition expands Alcon's leading portfolio of ocular health products, including several leading treatments for the temporary relief of dry eye symptoms.

"With the acquisition of Tear Film, we're excited to bring this latest innovation to treat the millions of people around the world who suffer from dry eye," said Andy Pawson, Alcon President & General Manager, Global Vision Care Franchise. "Alcon remains committed to improving the lives of patients around the world through innovative technologies like the iLux Device to address significant unmet needs in eye care."

The iLux Device received 510(k) clearance from the FDA in December 2017, and was officially launched by Tear Film in May 2018 at the annual meeting of the American Society for Cataract and Refractive Surgery.

"Since launching the iLux Device earlier this year, we've seen an enthusiastic response from eye care professionals who have already begun to incorporate it as an advanced treatment option for patients suffering from Meibomian Gland Dysfunction," said Rob Thornhill, CEO of Tear Film. "Now, as part of Alcon, we're eager to bring this technology to even more offices throughout the world."

The iLux Device is currently available in the US and Canada. Alcon expects to announce plans to expand to other countries in 2019.

Read More

Related news

New HCP Kit for automated impurity analysis of biotherapeutics

New HCP Kit for automated impurity analysis of biotherapeutics

21 Jun 2019

Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows.

Read more 
Sanofi and Google to develop new healthcare Innovation Lab

Sanofi and Google to develop new healthcare Innovation Lab

20 Jun 2019

Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

Read more 
Catalent to purchase BMS manufacturing facility

Catalent to purchase BMS manufacturing facility

19 Jun 2019

Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Colorcon launches Opadry Enteric for use with hydro-alcoholic media

Colorcon launches Opadry Enteric for use with hydro-alcoholic media

17 Jun 2019

A fully formulated one-step system providing simple preparation and ease-of-use for film coating.

Read more 
SenzaGen granted its first patent for GARD potency biomarker test

SenzaGen granted its first patent for GARD potency biomarker test

16 Jun 2019

Company can now offer an animal-free test method to quantify the strength of an allergenic effect.

Read more 
Affordable measles and rubella vaccines using NevoLine manufacturing platform

Affordable measles and rubella vaccines using NevoLine manufacturing platform

14 Jun 2019

Univercells' propriety bioproduction platform has already proven success.

Read more 
Leaf Expression Systems launches first line of Hypertrans research products

Leaf Expression Systems launches first line of Hypertrans research products

13 Jun 2019

Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Combining IT and OT software to solve manufacturing’s most frequent challenges

Combining IT and OT software to solve manufacturing’s most frequent challenges

11 Jun 2019

PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.

Read more